A demonstration of how AI-driven signal detection surfaces expansion opportunities in your install base, identifies net-new targets, and delivers account-level intelligence your reps would spend weeks compiling manually.
AI-powered signal detection across your top accounts. Every signal below is real, sourced from public disclosures, press releases, earnings calls, and job postings from the past 12 months. We profiled 5 of your install-base accounts below - this same analysis can run across your entire customer book on a recurring basis.
Each account below includes an estimated opportunity size using a T-shirt scale based on two factors.
Roche announced a 5-year, $50B U.S. investment plan (April 2025): $700M fill/finish plant in Holly Springs, NC; $575M Spark Therapeutics gene therapy innovation center in Philadelphia (opening 2026, 500+ staff); AI-focused R&D hub in Massachusetts; facility upgrades across 7+ states.
Roche has a first-in-class CD20xCD3 bispecific portfolio (Lunsumio, Columvi, Cevostamab). NXT007, a next-gen bispecific for hemophilia A, is entering Phase III in 2026. ~18 programs expected to enter or graduate late-stage testing in next 18 months.
Roche pharma CEO stated at JPM25 they have ~$10B/year M&A capacity. Recent deals: Poseida Therapeutics ($1.1B, CAR-T/gene therapy, Jan 2025), 89bio ($7.3B, metabolic disease). Each acquisition adds new molecule types needing analytical workflows.
Pfizer is scaling Seagen's ADC platform: 4 marketed ADCs (Padcev, Adcetris, Tivdak, Tukysa) plus novel immune-stimulating antibody conjugates (ISACs) and next-gen payloads. ~20 pivotal study starts planned for 2026. Seagen's internal MS core group (led by John Valliere-Douglass) now folded into Pfizer analytical sciences.
Acquired Abzena's $200M+ biologics facility in Sanford, NC (purpose-built for complex biologics). $750M expansion of Kalamazoo, MI mRNA/biologics facility. Long-term strategic agreement with Samsung Biologics for commercial-scale ADC production.
$3B+ 10-year agreement with FUJIFILM Diosynth (Holly Springs, NC, operations starting 2025). $3.6B Tarrytown campus expansion (1,000 new jobs). $2B new Saratoga Springs, NY facility (1,000 jobs). New fill/finish in Rensselaer, NY. Total infrastructure investment exceeds $7B.
Currently posting: Scientist (Analytical Chemistry, LC-MS) - "biochemical characterization of emerging novel therapeutic modalities"; Senior Scientist (LC-MS) - supporting "all stages of drug development"; Senior Scientist (Protein Biochemistry). All in Tarrytown, NY.
BLA submitted to FDA for DB-OTO (AAV gene therapy for hearing loss, decision expected H1 2026). Pioneering siRNA technology for Alzheimer's, Huntington's, ALS. ~45 product candidates in clinical development.
Enhertu: $2.29B in H1 2025 (+29% YoY), FDA approvals expanding across indications. Datroway (Dato-DXd) approved for HR+/HER2- breast cancer + Priority Review for TNBC (Feb 2026). 8 wholly-owned ADC assets in clinical development. ADC market forecast to exceed $40B by 2029.
$50B U.S. commitment by 2030 (July 2025). $4.5B manufacturing hub in Albemarle County, VA - includes a plant dedicated to ADC production (600 jobs). $2B biologics expansion in Maryland. $1.5B ADC facility in Singapore (800+ hires) - first end-to-end ADC production site globally, operational by 2029.
EsoBiotec ($774M, in vivo cell therapy, May 2025). Modella AI (oncology R&D, Jan 2026). 23 total acquisitions to date (11 oncology, 7 immunotherapy). Each adds new molecule types requiring MS characterization.
Acquired Roche's Vacaville, CA biologics site ($1.2B, late 2024). Investing additional CHF 500M to expand mammalian capacity. Now the largest biologics CDMO in the US. New Visp, Switzerland facility ramping for commercial GMP from 2026.
Dedicated bioconjugation capacity increased 4x, operations expected 2026 (~180 new jobs). Two more suites + 200 jobs at Visp for 2028. Long-term bioconjugate supply contract signed Q3 2025. ADC market growing ~20% CAGR.
CHF 1.3B capex in 2025 - weighted toward mammalian, drug product, bioconjugates, and cell/gene therapy. Acquired Redberry SAS (rapid testing) Oct 2025. 11-12% further growth expected in 2026 with margin expansion above 32%.
Expansion activity, new manufacturing sites, and prospect locations across your addressable market.
AI-identified net-new targets that fit the Protein Metrics ideal customer profile - active in complex biologics, scaling analytical capabilities, and currently underserved by instrument-native software. None of these are on your customer page. We surfaced 7 high-fit targets below from a broader scan of 20+ companies matching your ICP - the full list is available as part of an ongoing engagement.
Prospects are scored and ranked by two weighted factors - with timing urgency as the primary driver.
IND cleared Jan 2026 for both CR-001 (PD-1 x VEGF bispecific) and CR-003 (ITGB6-targeted ADC). Second ADC IND (CR-002) targeted mid-2026. Hired Wenjie Cheng, PhD (ex-WuXi Biologics VP) as SVP Technical Operations - she's building the entire CMC and analytical infrastructure from scratch for 3 programs simultaneously.
$107M Series B just closed January 2026 (GV, J&J, Novartis Venture Fund). First-in-human trial of EPI-326 planned early 2026. Novel EpiTAC platform - bispecific antibodies for targeted extracellular protein degradation. Unique analytical challenges: characterizing degrader bispecifics with two functionally distinct binding arms.
Actively hiring MS-skilled analytical scientists now - Senior Scientist, Analytical Development ($162K-$189K) requiring MS expertise for ADCs, bispecifics, and cytokines. Post-restructuring lean team rebuilding analytical capability. FDA research collaboration to develop ADC reference materials and analytical standards. Cell-free synthesis platform produces novel dual-payload ADCs.
$80M additional financing (May 2025) specifically for CDMO expansion. 175,000 sq ft cGMP facility in Ohio. 50+ gene therapy developer clients. 25+ in-house AAV assays including mass spectrometry for capsid characterization. Currently hiring Scientist I, Analytical Development (Proteins) for "capsid characterization" and "LC-MS based potency assays."
Clinical-stage with proprietary engineered AAV capsids (not standard serotypes) - demanding especially rigorous MS characterization for full/empty/intermediate ratios, VP stoichiometry, and PTMs. Phase 1/2 for CAP-003 initiated 2025. Expanding AbbVie partnership increasing program throughput. Analytical Development listed as key function on careers.
Zanidatamab (Ziihera) approved - biliary tract cancer; sBLA for first-line HER2+ gastric expected Q1 2026. IND submissions for ZW209 (DLL3-targeting trispecific T-cell engager) and ZW1528 (multispecific) on track 1H 2026. Trispecifics are the most analytically demanding molecules to characterize by MS. 2025 revenue $106M (+39% YoY).
Pioneering Bicycle Drug Conjugates (BDCs) - constrained bicyclic peptides (~2 kDa) conjugated to cytotoxic payloads. Not antibodies, not small molecules. Phase 2/3 dose selection for zelenectide pevedotin expected Q1 2026. Published Feb 2026 on MS-based BDC characterization. Standard antibody workflows don't apply - an underserved niche.
The full worked example - what "going deep" looks like on a priority account. Lilly is not currently on your customer page, making this both an expansion and net-new opportunity. This is one deep dive. We can produce these for any account on your target list - weekly if needed.
| Facility | Investment | Focus | Status |
|---|---|---|---|
| Lilly Medicine Foundry (Lebanon, IN) | $4.5B | Clinical trial mfg - small molecules, biologics, nucleic acid therapies | Ground broken May 2025; first batch 2027 |
| Virginia (Goochland County) | $5B | First dedicated ADC + mAb API/drug product facility | Announced Sept 2025; ~2030 completion |
| Alabama (Huntsville) | $6B | Active pharmaceutical ingredient manufacturing | Construction begins 2026; ~2032 |
| Pennsylvania | $3.5B | Injectable medicine and device manufacturing | Construction begins 2026; ~2031 |
| European facility | $3B | Oral medicine manufacturing capacity | Announced 2025 |
Every new site will need analytical QC labs with MS software. The Medicine Foundry is the most immediate opportunity - software decisions are being made NOW for a facility going operational in 2027. Lilly is already hiring Analytical Scientists (Mass Spectrometry) in Lebanon, IN.
Specific Lilly programs that create direct demand for Protein Metrics' products.
39-amino-acid dual GIP/GLP-1 receptor agonist with C20 fatty diacid moiety. Manufactured via hybrid SPPS/LPPS at kilogram scale. $11.6B in Q4 2025 alone - manufacturing volume is staggering.
Sofetabart mipitecan (LY4170156): FRalpha-targeting ADC with exatecan payload. FDA Breakthrough Therapy designation for platinum-resistant ovarian cancer. 55% ORR at recommended Phase 2 dose. Now in Phase 3 (FRAmework-01). Additional PTK7 and Nectin-4 ADCs in development.
Aaron J. Cazy presented at CASSS Mass Spectrometry 2025 (September 24): "Streamlining Agile MS Workflows with Genedata Expressionist." Deployed within Lilly's Biotechnology Discovery Research (BDR) group. Eight months after deployment, described as "completely transformative." Three use cases presented: mispairing analysis for bispecifics, multi-assay workflows for ADCs, and traditional peptide mapping.
| Dimension | Genedata Expressionist | Protein Metrics Byos/Byosphere | Positioning |
|---|---|---|---|
| Deployment | Server-based enterprise (heavy IT footprint) | Desktop (Byos) + cloud enterprise (Byosphere) | Lower barrier to entry; start desktop, scale to enterprise |
| Intact Mass | Supported | Industry-leading deconvolution algorithms | Best-in-class for intact mass - PM advantage |
| ADC DAR | Supported via multi-assay workflows | Strong DAR and payload distribution | Head-to-head competitive; emphasize ease of use |
| Oligonucleotide | Supported | Byos Oligonucleotide workflow | Both cover it - relevant for Lilly's RNA push |
| Vendor neutrality | Supports major vendors | Supports all vendors; purpose-built for MS data | Byosphere more focused on MS vs. Genedata's broader platform |
Recommended Strategy
Don't try to displace Genedata from BDR - the relationship is fresh and described as "transformative." Instead, target greenfield opportunities: Medicine Foundry, Virginia ADC facility, Alabama API facility are all NEW sites where software decisions haven't been made. Target late-stage development and CMC/QC where Genedata hasn't expanded yet. Position as complement, not competitor. Your reps' existing relationships at Lilly are the warm entry point - we arm them with the right context and named contacts so they walk in prepared.
Real individuals verified through conference presentations, publications, career pages, and professional profiles.
| Name | Title | Group | Evidence | Relevance |
|---|---|---|---|---|
| Aaron J. Cazy | Senior Scientist | BDR / Analytical | CASSS Mass Spec 2025 speaker - Genedata Expressionist workflows | Competitor contact. Knows Genedata. Could evaluate Byos for gaps Genedata doesn't cover. |
| Olivia Huffman | Principal Scientist, Protein MS | Biotech Center (San Diego) | LinkedIn - designs intact and middle-down LC-MS/MS workflows | High priority. Directly relevant to Byos intact mass + peptide mapping strengths. |
| Ranajoy Majumdar | Senior Director, Analytical Development | Analytical Development | TheOrg - biophysical characterization of peptides/proteins | Decision-maker level. Oversees analytical development. |
| Lihua Huang | Senior Research Fellow, Bioprocess R&D | Lilly Research Labs (Indianapolis) | CASSS 2020 speaker - HCP profiling. Published on HDX-MS. | Senior technical influencer. Deep MS expertise in process development. |
| G. Jonah Rainey, PhD | Associate Vice President | Antibody Engineering | Speaking at PEGS 2026. 15+ years bispecific discovery. | Senior leader. Drives bispecific programs that generate analytical demand. |
| Todd Maloney | Research Advisor, Small Molecule Design | Lilly Research Labs (Indianapolis) | ASMS workshop co-organizer. Published on nucleic acid MS characterization. | Key influencer for nucleic acid/oligonucleotide MS (Byos Oligo workflow). |
| Melody Shahsavarian, PhD | Director, Data Strategy & Digital Transformation | San Diego | PEGS 2026 speaker - "Biologics AI Moonshot" initiative | Key informatics/data contact. Ideal for Byosphere enterprise pitch. |
| Gianna Pescatore | Sr. Scientist, BRD Analytical Development | BRD | CASSS speaker - ADC charge heterogeneity via icIEF + MS | Relevant for ADC characterization workflows. |
| Conference | Date | Location | Lilly Presence |
|---|---|---|---|
| PEGS Boston 2026 | May 11-15, 2026 | Boston, MA | G. Jonah Rainey, Jiangyan Feng, Melody Shahsavarian confirmed speakers |
| ASMS 2026 | May 31 - Jun 4, 2026 | San Diego | Todd Maloney (previous workshop co-organizer). ~6,300-7,000 attendees expected. |
| CASSS Mass Spec 2026 | Sep 15-18, 2026 | Rockville, MD | Lilly had 3+ speakers in 2025 (Cazy, Ma, Pescatore). Expect similar participation. |
The $4.5B Lilly Medicine Foundry in Lebanon, IN is the single best entry point. It handles small molecules, biologics, AND nucleic acid therapies - all relevant to PM. First batch expected 2027. 400 new hires including scientists and lab techs. Software decisions are being made NOW. Lilly is already posting Analytical Scientist (Mass Spectrometry) roles in Lebanon, IN.
The volume and seniority of openings (including an Executive Director role) signals a significant expansion of MS capabilities across multiple sites.
Persona-specific hooks - not templates, but angles that connect specific Lilly initiatives to PM's value. If your reps already have relationships with any of these contacts, the hooks below give them something specific to bring up at the next touchpoint.
Lilly's $5B Virginia ADC manufacturing facility will be the first fully integrated API + drug product site for bioconjugates. Reference sofetabart's breakthrough designation and the need for DAR analysis, conjugation site mapping, and stability methods at commercial scale. Position Byosphere as purpose-built for GMP MS data management with audit trails - distinct from discovery-stage tools. Offer a case study from another ADC manufacturer using Byosphere in a regulated environment.
Reference the Medicine Foundry's unique challenge: one campus producing small molecules, biologics, AND nucleic acid therapies, each with different MS characterization workflows. Byosphere provides a single enterprise platform that normalizes MS data across modalities and instrument vendors (Thermo, Waters, Agilent). Position as complementary to existing discovery tools. Reference the "Biologics AI Moonshot" initiative - structured MS data in Byosphere feeds downstream AI/ML.
With >$50B in manufacturing expansion and 4+ new U.S. sites coming online by 2030-2032, Lilly faces an unprecedented challenge in standardizing analytical QC methods across a distributed network. Tirzepatide peptide QC alone requires intact mass and peptide mapping at massive throughput. Byosphere enables centrally managed, validated MS workflows deployed identically across Lebanon, Virginia, Alabama, and Pennsylvania. Offer a demo showing tirzepatide-class peptide identity/purity analysis.
This deliverable is a snapshot. Here's how it becomes a continuous advantage for your sales team - without pulling reps off quota or waiting for IT approvals.
Took RC an afternoon. It would take a rep 2-3 weeks of manual research across earnings calls, press releases, job boards, and conference programs.
This intelligence runs weekly via our AI agent layer - monitoring expansion signals, manufacturing, M&A, hiring, and conferences across your entire addressable market.
We surface the contacts and intelligence. Your reps have the relationships. They walk into every conversation with the right context - their network becomes more effective, not replaced.
Pre-armed with competitive intel, named contacts, and event-driven entry points - without spending hours on research. The intelligence layer runs in the background while they close.
When you're ready to bring this to leadership, here are the numbers that matter.
No new headcount required. This isn't hiring a market research analyst or an SDR. It's an intelligence layer that augments the team you're already building.
No IT implementation. Starts as a managed service - no CRM integration, no security review, no procurement cycle. Just intelligence delivered weekly.
Competitive moat. 22% of life sciences execs have scaled AI; only 9% see returns (Deloitte, 2026). Most competitors are still doing this manually. First-mover advantage in your segment is real and measurable.
Measurable from week one. Track signals surfaced, outreach sent, meetings booked, and pipeline generated. If it doesn't drive action, stop. No long-term commitment required to start.
Three Ways to Start
Matched to where you are right now - no big-bang implementation required.
Weekly signal monitoring + recurring intelligence reports like this one - covering your full account list and target market. RC handles everything, your team consumes and acts.
Lowest barrier. No CRM access or IT involvement needed. Start in one week.
Focused campaign building on the net-new prospects surfaced here. Evidence-matched outreach, multi-channel cadence. Your reps' existing relationships are the warm entry point - RC arms them with context and drafts.
4-6 week sprint. Measurable pipeline from the accounts in this document.
Intelligence layer + outreach + CRM integration. Signals push directly into Salesforce as account notes and tasks. Draft sequences loaded into your outreach tool. Your reps see "New signal" on their account page.
The destination once the team sees the value. Requires CRM access + IT coordination.
This isn't a platform you need to buy and implement. It's a service that runs alongside your existing workflow. Your reps keep selling. Their network is the distribution channel - we just make sure they walk in with the sharpest intelligence in the room.
The deliverable is the evaluation. If this was useful, imagine it running every week.